PTP Accounts Production v24.1.4.33 03687340 Board of Directors 1.1.23 31.12.23 31.12.23 false true false false true false iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh036873402022-12-31036873402023-12-31036873402023-01-012023-12-31036873402021-12-31036873402022-01-012022-12-31036873402022-12-3103687340ns15:EnglandWales2023-01-012023-12-3103687340ns14:PoundSterling2023-01-012023-12-3103687340ns10:Director12023-01-012023-12-3103687340ns10:PrivateLimitedCompanyLtd2023-01-012023-12-3103687340ns10:SmallEntities2023-01-012023-12-3103687340ns10:AuditExempt-NoAccountantsReport2023-01-012023-12-3103687340ns10:SmallCompaniesRegimeForDirectorsReport2023-01-012023-12-3103687340ns10:SmallCompaniesRegimeForAccounts2023-01-012023-12-3103687340ns10:FullAccounts2023-01-012023-12-3103687340ns10:Director22023-01-012023-12-3103687340ns10:CompanySecretary12023-01-012023-12-3103687340ns10:RegisteredOffice2023-01-012023-12-3103687340ns5:CurrentFinancialInstruments2023-12-3103687340ns5:CurrentFinancialInstruments2022-12-3103687340ns5:ShareCapital2023-12-3103687340ns5:ShareCapital2022-12-3103687340ns5:RetainedEarningsAccumulatedLosses2023-12-3103687340ns5:RetainedEarningsAccumulatedLosses2022-12-3103687340ns5:PlantMachinery2023-01-012023-12-3103687340ns5:PlantMachinery2022-12-3103687340ns5:PlantMachinery2023-12-3103687340ns5:PlantMachinery2022-12-3103687340ns5:CostValuation2022-12-3103687340ns5:CurrentFinancialInstrumentsns5:WithinOneYear2023-12-3103687340ns5:CurrentFinancialInstrumentsns5:WithinOneYear2022-12-31
REGISTERED NUMBER: 03687340 (England and Wales)















Unaudited Financial Statements

for the Year Ended 31 December 2023

for

Pharmaceutical Management Intelligence
Limited

Pharmaceutical Management Intelligence
Limited (Registered number: 03687340)






Contents of the Financial Statements
for the Year Ended 31 December 2023




Page

Company Information 1

Balance Sheet 2

Notes to the Financial Statements 3


Pharmaceutical Management Intelligence
Limited

Company Information
for the Year Ended 31 December 2023







DIRECTORS: K W Boyce
Mrs A Boyce





SECRETARY: Mrs A Boyce





REGISTERED OFFICE: 11 Chartmoor Road
Leighton Buzzard
Bedfordshire
LU7 4WG





REGISTERED NUMBER: 03687340 (England and Wales)





ACCOUNTANT: Roberts Accountancy & Tax Limited
11 Chartmoor Road
Leighton Buzzard
Bedfordshire
LU7 4WG

Pharmaceutical Management Intelligence
Limited (Registered number: 03687340)

Balance Sheet
31 December 2023

2023 2022
Notes £    £   
FIXED ASSETS
Tangible assets 4 291 676
Investments 5 445 445
736 1,121

CURRENT ASSETS
Debtors 6 3,750 2,400
Cash at bank and in hand 20,190 67,908
23,940 70,308
CREDITORS
Amounts falling due within one year 7 (6,497 ) (38,879 )
NET CURRENT ASSETS 17,443 31,429
TOTAL ASSETS LESS CURRENT
LIABILITIES

18,179

32,550

CAPITAL AND RESERVES
Called up share capital 1,877 1,877
Retained earnings 16,302 30,673
SHAREHOLDERS' FUNDS 18,179 32,550

The company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 December 2023.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 December 2023 in accordance with Section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for:
(a)ensuring that the company keeps accounting records which comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the company as at the end of each financial year and of its profit or loss for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the company.

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 9 September 2024 and were signed on its behalf by:





K W Boyce - Director


Pharmaceutical Management Intelligence
Limited (Registered number: 03687340)

Notes to the Financial Statements
for the Year Ended 31 December 2023

1. STATUTORY INFORMATION

Pharmaceutical Management Intelligence Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

2. ACCOUNTING POLICIES

Basis of preparing the financial statements
These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

Tangible fixed assets
Depreciation is provided at the following annual rates in order to write off each asset over its estimated useful life.
Plant and machinery etc - 33% on cost

Investments in subsidiaries
Investments in subsidiary undertakings are recognised at cost.

Taxation
Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

Current or deferred taxation assets and liabilities are not discounted.

Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the balance sheet date.

Deferred tax
Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date.

Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Pension costs and other post-retirement benefits
The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

3. EMPLOYEES AND DIRECTORS

The average number of employees during the year was 2 (2022 - 2 ) .

Pharmaceutical Management Intelligence
Limited (Registered number: 03687340)

Notes to the Financial Statements - continued
for the Year Ended 31 December 2023

4. TANGIBLE FIXED ASSETS
Plant and
machinery
etc
£   
COST
At 1 January 2023
and 31 December 2023 3,827
DEPRECIATION
At 1 January 2023 3,151
Charge for year 385
At 31 December 2023 3,536
NET BOOK VALUE
At 31 December 2023 291
At 31 December 2022 676

5. FIXED ASSET INVESTMENTS
Shares in
group
undertakings
£   
COST
At 1 January 2023
and 31 December 2023 445
NET BOOK VALUE
At 31 December 2023 445
At 31 December 2022 445

6. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Trade debtors 3,750 2,400

7. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2023 2022
£    £   
Taxation and social security 2,155 19,041
Other creditors 4,342 19,838
6,497 38,879

8. DIRECTORS' ADVANCES, CREDITS AND GUARANTEES

During the period the company paid dividends of £15,700 (2022 : £64,400) to the director and his wife.